Cited 24 times in
Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 장인익 | - |
dc.date.accessioned | 2016-02-04T11:15:32Z | - |
dc.date.available | 2016-02-04T11:15:32Z | - |
dc.date.issued | 2015 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/140022 | - |
dc.description.abstract | We investigated whether impaired regulation of bone morphogenetic protein-2 (BMP-2) via epigenetic pathways is associated with renal cell carcinoma (RCC) pathogenesis. Expression and CpG methylation of the BMP-2 gene were analyzed using RCC cell lines, and 96 matched RCC and normal renal tissues. We also performed functional analysis using BMP-2 restored RCC cells. A significant association of BMP-2 mRNA expression was also found with advanced tumor stage and lymph node involvement, while lower BMP-2 mRNA expression was significantly associated with poor overall survival after radical nephrectomy. In RCC cells, BMP-2 restoration significantly inhibited cell proliferation, migration, invasion, and colony formation. In addition, BMP-2 overexpression induced p21(WAF1/CIP1) and p27(KIP1) expression, and cellular apoptosis in RCC cells. BMP-2 mRNA expression was significantly enhanced in RCC cells by 5-aza-2'-deoxycitidine treatment. The prevalence of BMP-2 promoter methylation was significantly greater and BMP-2 mRNA expression was significantly lower in RCC samples as compared to normal kidney samples. Furthermore, a significant correlation was found between BMP-2 promoter methylation and mRNA transcription in tumors. Aberrant BMP-2 methylation and the resultant loss of BMP-2 expression may be a useful molecular marker for designing improved diagnostic and therapeutic strategies for RCC. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 9577~9591 | - |
dc.relation.isPartOf | ONCOTARGET | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antimetabolites, Antineoplastic/pharmacology | - |
dc.subject.MESH | Apoptosis | - |
dc.subject.MESH | Azacitidine/analogs & derivatives | - |
dc.subject.MESH | Azacitidine/pharmacology | - |
dc.subject.MESH | Bone Morphogenetic Protein 2/biosynthesis | - |
dc.subject.MESH | Bone Morphogenetic Protein 2/genetics* | - |
dc.subject.MESH | Carcinoma, Renal Cell/genetics* | - |
dc.subject.MESH | Carcinoma, Renal Cell/metabolism | - |
dc.subject.MESH | Carcinoma, Renal Cell/mortality | - |
dc.subject.MESH | Carcinoma, Renal Cell/surgery | - |
dc.subject.MESH | Cell Line, Tumor | - |
dc.subject.MESH | DNA Methylation*/drug effects | - |
dc.subject.MESH | Down-Regulation | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Gene Expression Regulation, Neoplastic*/drug effects | - |
dc.subject.MESH | Genes, cdc | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kidney Neoplasms/genetics* | - |
dc.subject.MESH | Kidney Neoplasms/metabolism | - |
dc.subject.MESH | Kidney Neoplasms/mortality | - |
dc.subject.MESH | Kidney Neoplasms/surgery | - |
dc.subject.MESH | Kidney Tubules/metabolism | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Proteins/biosynthesis | - |
dc.subject.MESH | Neoplasm Proteins/genetics* | - |
dc.subject.MESH | Nephrectomy | - |
dc.subject.MESH | Promoter Regions, Genetic/drug effects | - |
dc.subject.MESH | Promoter Regions, Genetic/genetics | - |
dc.subject.MESH | RNA, Messenger/biosynthesis | - |
dc.subject.MESH | RNA, Messenger/genetics | - |
dc.subject.MESH | RNA, Neoplasm/biosynthesis | - |
dc.subject.MESH | RNA, Neoplasm/genetics | - |
dc.subject.MESH | Recombinant Fusion Proteins/biosynthesis | - |
dc.subject.MESH | Recombinant Fusion Proteins/genetics | - |
dc.subject.MESH | Transfection | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways. | - |
dc.type | Article | - |
dc.contributor.college | College of Dentistry (치과대학) | - |
dc.contributor.department | Dept. of Oral Biology (구강생물학) | - |
dc.contributor.googleauthor | Yozo Mitsui | - |
dc.contributor.googleauthor | Hiroshi Hirata | - |
dc.contributor.googleauthor | Naoko Arichi | - |
dc.contributor.googleauthor | Miho Hiraki | - |
dc.contributor.googleauthor | Hiroaki Yasumoto | - |
dc.contributor.googleauthor | Inik Chang | - |
dc.contributor.googleauthor | Shinichiro Fukuhara | - |
dc.contributor.googleauthor | Soichiro Yamamura | - |
dc.contributor.googleauthor | Varahram Shahryari | - |
dc.contributor.googleauthor | Guoren Deng | - |
dc.contributor.googleauthor | Sharanjot Saini | - |
dc.contributor.googleauthor | Shahana Majid | - |
dc.contributor.googleauthor | Rajvir Dahiya | - |
dc.contributor.googleauthor | Yuichiro Tanaka | - |
dc.contributor.googleauthor | Hiroaki Shiina | - |
dc.identifier.doi | 10.18632/oncotarget.3445 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03461 | - |
dc.relation.journalcode | J02421 | - |
dc.identifier.eissn | 1949-2553 | - |
dc.identifier.pmid | 25797254 | - |
dc.subject.keyword | DNA methylation | - |
dc.subject.keyword | bone morphogenetic protein 2 | - |
dc.subject.keyword | molecular marker | - |
dc.subject.keyword | renal cell carcinoma | - |
dc.contributor.alternativeName | Chang, In Ik | - |
dc.contributor.affiliatedAuthor | Chang, In Ik | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 6 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 9577 | - |
dc.citation.endPage | 9591 | - |
dc.identifier.bibliographicCitation | ONCOTARGET , Vol.6(11) : 9577-9591, 2015 | - |
dc.identifier.rimsid | 45579 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.